How to Prepare for FY26 CDMRP Pre-Announcements Before the Solicitations Drop

Your TL;DR: The Department of War (DoW) has released FY26 pre-announcements for multiple CDMRP programs, including HRRP, MRP, MSRP, PRCRP, and TSCRP. These are signals, not full solicitations, which means this is the strategic window. Teams that treat pre-announcements as early planning documents, not placeholders, are the ones ready when timelines tighten.

The Signal Behind the Pre-Announcements

The Congressionally Directed Medical Research Programs have released FY26 pre-announcements for:

  • The Melanoma Research Program (MRP) released a pre-announcement for the following anticipated funding opportunities:

  • The Multiple Sclerosis Research Program (MSRP) released a pre-announcement for the following anticipated funding opportunities:

  • The Peer-Reviewed Cancer Research Program (PRCRP) released a pre-announcement for the following anticipated funding opportunities:
    • Idea Award (New: Established Investigator Option and Early-Career Investigator Option)
    • Impact Award (with or without Partnering Principal Investigator Option)
    • Clinical Trial Award
    • To view the PRCRP pre-announcement visit https://cdmrp.health.mil/pubs/press/2026/prcrppreann

  • The Tuberous Sclerosis Complex Research Program (TSCRP) released a pre-announcement for the following anticipated funding opportunities:

A pre-announcement is not a formality. It is a directional flare. It tells the research community where Congressional intent and DoW priorities are aligning for the fiscal year. If you are considering any of these mechanisms, now is the time to pressure-test alignment and strategy rather than waiting for the full Program Announcements to drop. If it’s helpful, EBHC can review your concept now against typical CDMRP evaluation criteria so you are not reverse-engineering a strategy under deadline pressure later.

How CDMRP Is Different from Traditional NIH Funding

Researchers who approach CDMRP like NIH often misread the room. CDMRP programs are Congressionally directed and mission-driven. Review panels are built to assess not only scientific rigor, but also:

  • Relevance to the program’s stated military and patient community priorities
  • Potential impact, often in near- to mid-term horizons
  • Responsiveness to specific award intent, especially for Idea and Exploration mechanisms

These programs frequently prioritize innovation and impact over incremental advancement. An Idea Award under PRCRP or MRP, for example, is rarely about extending prior work. It is about advancing something that shifts the conversation.

The GAP shows up when investigators submit technically excellent science that fails to clearly articulate why it matters to the program’s defined community or how it accelerates meaningful change.

What the Award Mix Is Telling Us

There are patterns in this year’s pre-announcements worth noting. First, multiple programs are emphasizing Idea, Exploration, and Hypothesis Development awards. That signals appetite for bold, early-stage thinking, provided it is grounded in a credible rationale. Second, Clinical Trial Awards are present in MSRP and PRCRP. That suggests continued support for translation, not just discovery. Third, the PRCRP’s new Established Investigator and Early Career Investigator options within the Idea Award indicate structural refinement. CDMRP is clarifying lanes. That typically means closer scrutiny of eligibility fit and career-stage positioning. Finally, mechanisms such as the Melanoma Academy Scholar Award and Team Science Award reinforce that CDMRP continues to value structured mentorship models and collaborative ecosystems, not just individual PIs.

What Smart Teams Are Doing Right Now

The strongest applicants use the pre-announcement window to:

  • Revisit specific program investment strategies and prior funded abstracts
  • Confirm eligibility nuances and investigator status
  • Map their concept directly to the anticipated award intent
  • Identify patient advocate integration plans where required
  • Begin internal compliance planning for budgets and regulatory components

This is especially critical for Clinical Trial Awards and larger team-based mechanisms. Institutional routing, subawards, and regulatory documentation do not materialize overnight. EBHC routinely advises research teams during this pre-announcement phase, when there is still time to refine scope, reposition aims, or even decide that a different mechanism is strategically stronger.

Why Waiting Is Risky

Full solicitations often arrive with tight turnaround times. By then, the intellectual framing should already be settled. Investigators who wait for the official Program Announcement frequently find themselves reshaping aims to fit eligibility constraints or scrambling to integrate required elements such as community engagement or military relevance statements.

CDMRP review is competitive and impact-driven. Clarity of alignment is rarely accidental.

If you are deciding whether to pursue one of these FY26 CDMRP opportunities, an early strategic assessment can clarify fit, competitiveness, and resource allocation before institutional calendars fill up. https://cdmrp.health.mil/

Treat Pre-Announcements as Planning Documents

Pre-announcements are not placeholders. They are giving advance notice that funding lanes are forming. HRRP, MRP, MSRP, PRCRP, and TSCRP are signaling where DoW-backed medical research dollars are likely to flow in FY26. The teams that respond thoughtfully now, rather than reactively later, position themselves for stronger submissions and fewer structural surprises.

If you would like a strategic read on which CDMRP mechanism best matches your research trajectory, EBHC can provide experienced guidance grounded in how these programs are evaluated and how proposals tend to succeed or stall.

Ready To Take the Next Step?

Schedule a Consult Call

We assist our clients in locating, applying for, and evaluating the outcomes of non-dilutive grant funding. We believe non-dilutive funding is a crucial tool for mitigating investment risks, and we are dedicated to guiding our clients through the entire process—from identifying the most suitable opportunities to submitting and managing grant applications.